Nektar Therapeutics short interest in 2025
In 2025, Nektar Therapeutics's disclosed short interest ran from 2.56% of shares outstanding on 15 Jan 2025 to 14.43% on 31 Dec 2025, a change of +11.87 percentage points. The year's high was 14.43% on 31 Dec 2025 and its low 2.56% on 15 Jan 2025, averaging 6.48% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.32 days on 30 May 2025. Full history: Nektar Therapeutics.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 2.56% (15 Jan 2025)
- End of year
- 14.43% (31 Dec 2025)
- Change
- +11.87 pp
- High
- 14.43% (31 Dec 2025)
- Low
- 2.56% (15 Jan 2025)
- Average
- 6.48%
- Highest days to cover
- 7.32 (30 May 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 2.56% | 2.59 | |
| 31 Jan 2025 | 3.12% | 4.83 | |
| 14 Feb 2025 | 4.05% | 1.75 | |
| 28 Feb 2025 | 3.59% | 3.08 | |
| 14 Mar 2025 | 3.77% | 4.83 | results (8-K), 10-K filed |
| 31 Mar 2025 | 4.21% | 4.75 | |
| 15 Apr 2025 | 4.41% | 2.33 | |
| 30 Apr 2025 | 4.84% | 4.90 | |
| 15 May 2025 | 5.73% | 4.87 | results (8-K), 10-Q filed |
| 30 May 2025 | 6.07% | 7.32 | |
| 31 Jul 2025 | 5.40% | 1.36 | |
| 15 Aug 2025 | 5.44% | 1.49 | results (8-K), 10-Q filed |
| 29 Aug 2025 | 5.87% | 1.88 | |
| 15 Sep 2025 | 8.45% | 1.00 | |
| 30 Sep 2025 | 10.36% | 1.51 | |
| 15 Oct 2025 | 9.11% | 2.42 | |
| 31 Oct 2025 | 7.24% | 1.57 | |
| 14 Nov 2025 | 8.92% | 2.40 | results (8-K), 10-Q filed |
| 28 Nov 2025 | 8.94% | 2.94 | |
| 15 Dec 2025 | 9.47% | 3.31 | |
| 31 Dec 2025 | 14.43% | 2.29 |
See also: Nektar Therapeutics's full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.